Immunoglobulin, Antibody, Or Fragment Thereof, Other Than Immunoglobulin Antibody, Or Fragment Thereof That Is Conjugated Or Adsorbed Patents (Class 530/387.1)
  • Patent number: 10336822
    Abstract: This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: July 2, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Vesna D. Garovic
  • Patent number: 10336818
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 2, 2019
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 10330650
    Abstract: The present invention relates to a high performance liquid chromatography method for polypeptide mixtures. Specifically, the method including the following steps: step (1): preparing a solution of the glatiramer acetate to be tested; step (2): performing gradient elution on a sample to be tested with an anion exchange liquid chromatography, a cation exchange liquid chromatography, or a reversed-phase liquid chromatography; step (3): determining a peak area corresponding to each component of the glatiramer acetate, comparing the peak area with to a peak area of a reference substance to determine whether the content of each component of the sample to be tested is in a qualified range.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: June 25, 2019
    Assignee: HYBIO PHARMACEUTICAL CO., LTD.
    Inventors: Yangming Tang, Gang He, Guotao Li, Anjin Tao, Jiancheng Yuan
  • Patent number: 10316327
    Abstract: An insect-resistant and/or fungi-resistant transgenic plant. The plant may be transformed with a gene construct including at least one gene chosen from LECRPA1, LECRPA2, and LECRPA3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 11, 2019
    Inventors: Yi Li, Lisa Hollister
  • Patent number: 10308715
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 4, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda
  • Patent number: 10301389
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 28, 2019
    Assignee: IMAGINAB, INC.
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Patent number: 10301388
    Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: May 28, 2019
    Assignee: Eureka Therapeutics, Inc.
    Inventors: Hong Liu, Jingwei Lu, Zhiyuan Yang, Li Long, Neal Cheng
  • Patent number: 10273270
    Abstract: An object of the present invention is to create a novel engineered Protein A ligand having better antibody dissociation properties in the acidic condition compared with known engineered Protein A ligands. The present invention provides a protein having an affinity for an immunoglobulin, including an amino acid sequence obtained by introducing, into an amino acid sequence derived from any of E, D, A, B and C domains of Protein A, at least one amino acid substitution at any one or more of amino acid residues corresponding to positions 31 to 37 of the A, B and C domains (positions 29 to 35 of the E domain, positions 34 to 40 of the D domain), which are conserved in all the domains, the protein having a lower affinity for an Fab region of an immunoglobulin than a protein having the amino acid sequence before introduction of the substitution.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: April 30, 2019
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata, Shunichi Taira, Masayuki Takano, Keita Iguchi, Yoshiyuki Nakano
  • Patent number: 10221245
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: March 5, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • Patent number: 10206983
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 19, 2019
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda Guth, Leah Mitchell
  • Patent number: 10208109
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: February 19, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas R. Striebinger, Patrick Keller
  • Patent number: 10208120
    Abstract: The invention provides dual specific anti-FGFR2 and FGFR3 (FGFR2/3) antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 19, 2019
    Assignee: GENENTECH, INC.
    Inventors: Yiyuan Yin, Avi Ashkenazi, Paul J. Carter, Mark Chen, Junichiro Sonoda
  • Patent number: 10196452
    Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 5, 2019
    Assignees: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. Leblanc, Haichun Huang
  • Patent number: 10189896
    Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
    Type: Grant
    Filed: December 16, 2017
    Date of Patent: January 29, 2019
    Assignee: PFIZER INC.
    Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
  • Patent number: 10106600
    Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: October 23, 2018
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Harald Duerr, Christian Klein, Erhard Kopetzki, Wilma Lau, Joerg Thomas Regula, Juergen Michael Schanzer, Pablo Umana, Katharina Wartha
  • Patent number: 10100124
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: October 16, 2018
    Assignees: Daiichi Sankyo Europe GmbH, AMGEN, INC.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Susanne Hartmann, Larry L. Green
  • Patent number: 10094833
    Abstract: The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 9, 2018
    Assignee: Randox Laboratories Limited
    Inventors: Clifford Taggart, Sinead Weldon, Chris Scott
  • Patent number: 10087250
    Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: October 2, 2018
    Assignee: Roche Glycart AG
    Inventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umaña
  • Patent number: 10077306
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: September 18, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
  • Patent number: 10072295
    Abstract: The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital analysis is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: September 11, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Stephen Quake, Hei-Mun Christina Fan
  • Patent number: 10040861
    Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 7, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Rinpei Niwa, Mami Tsuchiya
  • Patent number: 10040053
    Abstract: The objective of the present invention is to provide to a method for easily producing high-performance porous cellulose beads having high mechanical strength. Also, the objective of the present invention is to provide an adsorbent produced from the high-performance porous cellulose beads. According to the present invention, high-performance porous cellulose beads can be easily produced from porous cellulose beads, and an adsorbent having high strength and high adsorption amount can be easily produced from the high-performance porous cellulose beads.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 7, 2018
    Assignee: KANEKA CORPORATION
    Inventors: Kento Kanaya, Yoshikazu Kawai, Takahiro Okubo, Ken-ichiro Morio
  • Patent number: 10023634
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 17, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
  • Patent number: 10018635
    Abstract: The present invention relates to methods for continuous or near-continuous separation and purification of samples, particularly biological samples, to reduce the number or volume of non-targeted analytes in those samples to enable improved mass spectrometric analysis of analytes of interest, and apparatuses for conducting those methods, utilizing a transport agent with a core domain and a binding domain, the transport agent exceeding 200 kiloDaltons or 10 nm, and the binding domain targeted to the analytes of interest, in conjunction with size-exclusion based chromatography to separate the transport agent-analyte of interest complex from non-targeted analytes that are not bound, or are only non-specifically bound, to the transport agent.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 10, 2018
    Inventors: Fred Regnier, JinHee Kim
  • Patent number: 9994632
    Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor through Ang2, and methods of using the same.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 12, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seok Kyun Kim, Sunghyun Kim, Sang Yeul Han, Seung Hyun Lee, Su Jin Kim, Yong In Kim, Hyung-Chan Kim, Kwang Hoon Lee, Hyo Seon Lee
  • Patent number: 9933442
    Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: April 3, 2018
    Assignee: LSI MEDIENCE CORPORATION
    Inventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
  • Patent number: 9913898
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: March 13, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Patent number: 9913900
    Abstract: The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 13, 2018
    Assignees: AMGEN INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Hua Zhu Ke, Min Liu, William V. Giannobile
  • Patent number: 9896503
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: February 20, 2018
    Assignee: Philogen S.P.A.
    Inventors: Jascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
  • Patent number: 9895437
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: February 20, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Patent number: 9884115
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 6, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Patent number: 9879072
    Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: January 30, 2018
    Assignee: AMGEN INC.
    Inventors: William Gleason Richards, Hsieng Sen Lu, Hua Zhu Ke, Chaoyang Li, Frederick W. Jacobsen
  • Patent number: 9868780
    Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 16, 2018
    Assignee: Morphotek, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Patent number: 9822143
    Abstract: This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 21, 2017
    Assignee: Wyeth LLC
    Inventors: Shujun Sun, Christopher Gallo, Brian Kelley
  • Patent number: 9815895
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 14, 2017
    Assignees: BIOWA, INC., ASTRAZENECA AB
    Inventors: Masamichi Koike, George L. Spitalny, Alistair Wheeler, Barbara White
  • Patent number: 9765148
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 19, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Patent number: 9765149
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 19, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Patent number: 9753039
    Abstract: The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 5, 2017
    Assignee: B.R.A.H.M.S GmbH
    Inventors: Joachim Struck, John GF Cleland
  • Patent number: 9725511
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 8, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 9683032
    Abstract: Anti-S100A4 antibody molecules that are capable of inhibiting the biological activity of S100A4 in promoting tumor progression and/or in inducing tumor metastasis are described. The antibody molecules are also useful in the treatment of inflammatory conditions. The properties of the antibodies are demonstrated using in vitro and in vivo assays.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: June 20, 2017
    Assignee: Cancer Research Technology Limited
    Inventors: Jorg Klingelhöfer, Noona Ambartsumian, Mariam Grigorian, Eugene Lukanidin
  • Patent number: 9669107
    Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 6, 2017
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yongzu Kim, Taekyo Park, Sungho Woo, Hyangsook Lee, Sunyoung Kim, Jongun Cho, Doohwan Jung, Youngun Kim, Hyunjin Kwon, Kyuman Oh, Yunseo Chung, Yun-Hee Park
  • Patent number: 9657054
    Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: May 23, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Patent number: 9644031
    Abstract: Provided are an improved EGFR antibody or a functional segment thereof, comprising an engineered heavy chain and light chain. Specifically, the antibody is an engineered whole human-source monoclonal antibody. Also provided is a method for manufacturing said whole human-source antibody and usage of the antibody in the manufacture of medicines used for the treatment of tumors.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: May 9, 2017
    Assignees: GENRIX (SHANGHAI) BIOPHARMACERTICAL CO., LTD., BIOEX THERAPEUTICS INC.
    Inventors: Jie Liu, Zhuobing Zhang, Jikuan Shan, Wei Suo
  • Patent number: 9636420
    Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: May 2, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 9631026
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: April 25, 2017
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Patent number: 9631011
    Abstract: The present invention relates to a Gremlin-1 antibody that inhibits Gremlin-1 in a manner independent of bone morphogenetic protein (BMP) or vascular endothelial growth factor receptor-2 (VEGFR-2), thus providing the effect of treating cancer. The antibody of the present invention inhibits cell migration, cell invasion and cell proliferation which are dependent on Gremlin-1, and therefore, can be effectively used in treating cancer or immune disease.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 25, 2017
    Assignee: SNU R&DB FOUNDATION
    Inventors: Hyun Kee Kim, Junho Chung, Min Soo Kim, Soo Min Yoon
  • Patent number: 9624310
    Abstract: A bispecific antibody format devoid of an active Fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on B-cells, for use in the treatment or prevention of B cell mediated autoimmune diseases.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: April 18, 2017
    Inventor: Gundram Jung
  • Patent number: 9581596
    Abstract: A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: February 28, 2017
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Mike Powell, Akins Doherty, Chamberlain Obialo
  • Patent number: 9573990
    Abstract: The present invention relates to a method for producing high affinity antibodies that are antigen-specific. The method involves binding a plurality of antibody-producing B-cells from a mammal to a plurality of cognate antigens; sorting the bound antibody-producing B-cell and cognate antigen; amplifying nucleic acid sequences encoding each antibody, or fragment thereof, from the B-cells; and expressing the each antibody in a protein expression system. Antibodies produced in this manner are useful in diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: February 21, 2017
    Assignee: MONTECITO BIO-SCIENCES, LTD.
    Inventor: Jorn Gorlach
  • Patent number: 9562109
    Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: February 7, 2017
    Assignee: Zymeworks Inc.
    Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon